Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label phase II dose-optimization study of SMP-656 monotherapy in HER2-positive advanced or metastatic breast cancer after progression on a HER2-targeted topoisomerase inhibitor ADC
CTR20261695Phase 2Active
- Sponsor
- Kelinyuan Pharmaceutical
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SMP-656 in breast cancer, sponsored by Kelinyuan Pharmaceutical. Started May 2026; status: active.
02
Drugs
SMP-656
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20261695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261695.